| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Melissa R. Bussey | |
| Rochella A. Ostrowski | |||
| Walter M. Jay | |||
| Yasmin Shayesteh | |||
| P2860 | cites work | Recent developments in thyroid eye disease | Q24564205 |
| Autoimmunity and Graves' disease | Q27022771 | ||
| Graves' ophthalmopathy | Q28274196 | ||
| Clinical features of Graves' ophthalmopathy in an incidence cohort | Q28275743 | ||
| Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy | Q33624477 | ||
| Why is the thyroid so prone to autoimmune disease? | Q34025839 | ||
| Cutting edge: the etiology of autoimmune thyroid diseases | Q35085745 | ||
| The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. | Q36462675 | ||
| Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment | Q36525240 | ||
| Regulation of Lymphocyte Function by PPARgamma: Relevance to Thyroid Eye Disease-Related Inflammation | Q37114625 | ||
| TSH receptor autoantibodies | Q37426868 | ||
| Emerging pharmacotherapy for treatment of Graves' disease | Q37515491 | ||
| Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review | Q37720977 | ||
| B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. | Q38068619 | ||
| The autoimmunity in Graves's disease | Q38070522 | ||
| GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. | Q38093041 | ||
| Systemic adverse events following rituximab therapy in patients with Graves' disease. | Q40340279 | ||
| Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. | Q43042591 | ||
| Lid retraction and levator aponeurosis defects in Graves' eye disease. | Q43754016 | ||
| The role of the IL-23/IL-17 axis in the pathogenesis of Graves' disease | Q44388581 | ||
| Potential utility of rituximab for Graves' orbitopathy | Q45719549 | ||
| Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. | Q46285253 | ||
| Rituximab in relapsing Graves' disease, a phase II study. | Q46483075 | ||
| Rituximab for thyroid eye disease | Q46542384 | ||
| The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy. | Q50795971 | ||
| Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. | Q50933902 | ||
| Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy | Q58109526 | ||
| Modification of the Classification of the Eye Changes of Graves' Disease: Recommendations of the Ad Hoc Committee of The American Thyroid Association | Q67020629 | ||
| Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment | Q74238074 | ||
| The effect of Müllerectomy on Kocher sign | Q74760541 | ||
| Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study | Q79546631 | ||
| B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study | Q79734838 | ||
| Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion | Q80061323 | ||
| Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease | Q81070630 | ||
| Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease | Q81435428 | ||
| Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids | Q82359524 | ||
| Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action | Q83201756 | ||
| Prevention and handling of acute allergic and infusion reactions in oncology | Q84987391 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 109-115 | |
| P577 | publication date | 2015-06-17 | |
| P1433 | published in | Neuro-Ophthalmology | Q7002100 |
| P1476 | title | Rituximab in the Treatment of Thyroid Eye Disease: A Review | |
| P478 | volume | 39 |
| Q49962864 | Utility of rituximab treatment for exophthalmos, myxedema, and osteoarthropathy syndrome resistant to corticosteroids due to Graves' disease: a case report. | cites work | P2860 |
Search more.